Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine

Pia Raanani, Ofer Shpilberg*, Shmuel Gillis, Abraham Avigdor, Izhar Hardan, Miriam Berkowicz, Orit Sofer, Izidore Lossos, Angela Chetrit, Dina Ben-Yehuda, Isaac Ben-Bassat

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

We have assessed the outcome of 66 refractory and relapsed acute leukemia patients treated with high dose mitoxantrone and cytarabine. Therapy consisted of a total dose of 40-60 mg/m2 mitoxantrone and 3 g/m2 of cytarabine daily on 5 consecutive days. A total of 28 patients were treated for primary resistant and 38 patients for early or late relapsed leukemia. A total of 35 patients achieved CR. Four patients died during the induction course. Toxicity was acceptable and comparable to other salvage regimens. The median disease-free and overall survivals were 4 and 6 months, respectively. Although this regimen is effective in achieving remission in refractory leukemia, its duration is short.

Original languageEnglish
Pages (from-to)695-700
Number of pages6
JournalLeukemia Research
Volume23
Issue number8
DOIs
StatePublished - Aug 1999
Externally publishedYes

Keywords

  • Acute leukemia
  • HIDAC
  • Mitoxantrone
  • Refractory
  • Relapsed
  • Salvage

Fingerprint

Dive into the research topics of 'Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine'. Together they form a unique fingerprint.

Cite this